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Edited by Gunnar von Heijne and Anders LiljasAbstract Most types of DNA damage block the passage of the
replication machinery. In order to bypass these blocks, cells em-
ploy special translesion synthesis (TLS) DNA polymerases,
which have lower stringency than replicative polymerases.
DNA polymerase g is the major polymerase responsible for
bypassing UV lesions in DNA and its absence results in the var-
iant form of the genetic disorder, xeroderma pigmentosum.
Other TLS polymerases have speciﬁcities for diﬀerent types of
damage, but their precise roles inside the cell have not yet been
established. These polymerases are located in replication facto-
ries during DNA replication and the polymerase sliding clamp
PCNA plays an important role in mediating switching between
diﬀerent polymerases.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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pigmentosum1. Introduction
All cells are continually exposed to a wide variety of agents
that damage their DNA. These include endogenous reactions,
like hydrolysis and oxidation, and exposure to exogenous car-
cinogens, such as UV light and polycyclic hydrocarbons. To
counteract this damage, cells have evolved a complex series
of repair systems for removing most types of damage. Despite
the protection provided by these repair mechanisms, the repair
processes are in some cases slow and incomplete. In these cir-
cumstances, the cell is obliged to replicate DNA containing
persisting damage. The DNA replication apparatus is a ﬁnely
tuned machine designed to replicate DNA at great speed and
with high ﬁdelity. A consequence of this is that the highly strin-
gent replicative DNA polymerases are unable to accommodate
damaged bases in their active sites and therefore DNA lesions
block replication fork progression. In order to overcome this
potential disaster, cells have evolved further mechanisms for
either avoiding the damage or synthesising past lesions.
Damage avoidance mechanisms involve recombination with
the sister duplex to restore the lost information, but little is
understood about the detailed mechanisms of these processes
and they will not be discussed further in this review. Synthesis
past lesions (translesion synthesis – TLS) entails the use of*Fax: +44 1273 678121.
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doi:10.1016/j.febslet.2004.11.029specialised DNA polymerases, which have been adapted for
this function, and work on these polymerases over the last ﬁve
years has begun to give molecular insights into events occur-
ring at stalled replication forks. Most of the TLS polymerases
belong to the recently discovered Y-family [1]. They have lower
stringency than replicative polymerases and their active sites
are more open and can therefore accommodate damaged
bases. Wei Yang discusses this in detail in her review in this
volume. There are four Y-family polymerases in human cells,
polg, poli, polj and Rev1, and each one is able to carry out
TLS past diﬀerent lesions in vitro. Only in the case of polg
is its function in vivo understood.2. Polg
Xeroderma pigmentosum is a genetic disorder characterised
by extreme sensitivity of the skin to sunlight, together with
profound sunlight-induced skin pigmentation changes and an
enormously increased incidence of skin cancer [2,3]. In most
cases, these features result from a defect in nucleotide excision
repair (NER), but in 20% of patients, NER is unaﬀected.
These so-called XP variants (XPV) are deﬁcient in their ability
to replicate past UV damage [4]. XPV cells are, like their NER-
defective counterparts, extremely hypermutable by UV light [5]
and it is this UV hypermutability that presumably accounts for
XP variants skin cancer susceptibility. For many years, the
gene defective in XPV cells escaped identiﬁcation, but in
1999 it was isolated and found to encode the polymerase that
we now term polg [6,7]. The puriﬁed enzyme is able to repli-
cate eﬃciently past UV-induced cyclobutane pyrimidine di-
mers (CPD), in most cases inserting the correct bases
opposite the lesions [8]. Taken together, the ﬁndings with polg
and XPV cells suggest that TLS with polg is the major and
most eﬃcient way for cells to bypass UV-induced CPDs. In
its absence an alternative, less eﬃcient and more error-prone
mechanism is called into play. The upshot is an increased
UV mutability.
Using simple in vitro systems polg can bypass CPDs, but
how does it work at stalled replication forks in vivo? Within
the Y-family, the catalytic domain is well conserved and is in
most cases located at the N-terminus of the molecules. The
C-termini are poorly conserved between family members and
are presumably involved in protein–protein interactions. We
have shown that polg is localised in the nucleus, and that dur-
ing S phase it accumulates in nuclear foci that are the sites of
DNA replication (replication factories) [9]. Following UV-irra-
diation, the number of cells with S phase replication fociblished by Elsevier B.V. All rights reserved.
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age. The sequences required for localisation in the nucleus and
in nuclear foci are entirely contained in the C-terminal 120 aa
[9]. Within this domain, there are a C2H2 zinc ﬁnger, a bipar-
tite nuclear localisation signal and a PCNA-binding motif, all
of which are required for correct localisation of polg in repli-
cation foci (our unpublished data).Fig. 1. Model for TLS in mammalian cells. Blockage of the fork (1)
activates Rad6–Rad18, which mono-ubiquitinate PCNA (U) (2). This
increases the aﬃnity of PCNA for polg and enables polg to be
switched in (3), and to carry out TLS past the damage. After the
damage has been by-passed, replication by pold restarts (4).2.1. PCNA ubiquitination and the polymerase switch
Polg is therefore locally available in replication factories to
carry out TLS past UV damage, but how is it engaged at
blocked forks? It has long been known from genetic studies
in yeast that replication of DNA damage requires a series of
genes in the RAD6 epistasis group, whose function has only
been revealed quite recently. Five of these genes are involved
in ubiquitination. Rad18 is an E3 ubiquitin ligase, which binds
to both single-stranded DNA and to the Rad6 E2 ubiquitin
conjugator. Ubc13 and Mms2 form a heterodimer with E2
activity but forms chains linked through lys63 of ubiquitin
rather than the more frequent lys48 [10]. Ubc13–Mms2 inter-
acts with the E3 Rad5 [11]. The substrate for these ubiquitina-
tion systems was revealed by Hoege et al., who showed that,
following DNA damaging treatment, the polymerase accessory
protein PCNA became ubiquitinated [12]. PCNA is a homotri-
meric sliding clamp which is loaded onto the DNA at a primer
terminus and is required for replication by eukaryotic DNA
polymerases. After damage, mono-ubiquitination of PCNA
was eﬀected by Rad6–Rad18, whereas poly-ubiquitination
was mediated by Mms2–Ubc13 and Rad5. The authors pro-
posed that this ubiquitination of PCNA somehow brought
about the switch from replicative to TLS polymerase [12].
Using human cells, we have shown that PCNA is ubiquiti-
nated following treatment with UV or other agents that hinder
the progress of the replication fork. However, we were only
able to observe mono-ubiquitination [13]. We did not detect
poly-ubiquitination. The mono-ubiquitination requires the hu-
man orthologs of Rad6 and Rad18 [13,14]. Mono-ubiquitina-
tion of PCNA increases its aﬃnity for polg, so that in
chromatin there is a speciﬁc interaction between mono-ubiqui-
tinated PCNA and polg [13]. We thus envisage the following
sequence of events at the stalled replication fork (Fig. 1).
1. Fork blockage exposes single-stranded regions of DNA at
the site of the block.
2. Rad18 binds to the single-stranded DNA [15] and together
with Rad6 brings about the mono-ubiquitination of PCNA
[12–14].
3. Both mono-ubiquitinated PCNA and Rad18 interact with
polg and recruit it to the site of the blocked fork [13,14].
The increased aﬃnity for polg brings about the polymerase
switch. Polg displaces pold and, if the blockage is caused by
a CPD, polg carries out TLS past the lesion.
4. After the CPD is by-passed and the nascent chain is ex-
tended, polg dissociates and the more processive pold re-
sumes replication.
If the blocking lesion cannot be bypassed by polg, or in the
absence of polg in XP variants, an alternative mechanism for
bypassing the lesion needs to be found. At present, there is lit-
tle convincing evidence as to what goes on under these circum-
stances in vivo, and we can only speculate, based on their
properties in vitro and their localisation and interactions, that
other polymerases might be involved. Alternatively, the cellmay deal with the problem by instigating a recombinational
damage-avoidance mechanism (see review by Kannouche
and Stary) [16].3. Poli
Poli is a paralog of polg, both proteins being homologous to
Saccharomyces cerevisiae Rad30 (polg). In vitro poli can insert
nucleotides opposite various damaged bases, but it cannot
complete the bypass, as it is not able to extend from the in-
serted base [17]. Other polymerases are able to extend from in-
serted bases and it has been suggested that poli might act in
concert with another ‘‘extender’’ DNA polymerase to carry
out TLS past diﬀerent lesions [18]. Evidence in support of a
role for poli in TLS comes from its localisation, which is iden-
tical to that of polg, namely it is localised in the nucleus and
accumulates in replication foci [19]. This accumulation in foci
is dependent on PCNA, since mutation of a PCNA-binding
motif in poli abolishes its interaction with PCNA in vitro
and its localisation in replication foci in vivo [20]. Localisation
of poli in foci is also largely dependent on the presence of
polg, as it is much reduced in polg-deﬁcient XPV cells. More-
over polg and poli directly interact [19]. This tight co-ordina-
tion between polg and poli suggests a role for poli in TLS, but
the exact nature of this role remains to be determined.
Curiously, it transpires that the 129 strain of mice has an
amber mutation in the poli gene and makes no detectable poli
A.R. Lehmann / FEBS Letters 579 (2005) 873–876 875protein [21]. As yet no adverse eﬀects of this mutation have
been identiﬁed.4. Polj
Polj is the homolog of the PolIV (DinB) protein in Esceri-
chia coli. PolIV is involved in frameshift mutagenesis and in
some TLS reactions. In vitro polj is able to bypass benzo[a]-
pyrene (BaP)-guanine adducts quite eﬃciently and accurately
[22]. Polj-deﬁcient mouse cells are sensitive to both killing
and mutagenesis induced by BaP treatment [23]. Furthermore,
polj expression is upregulated by exposure of cells to polycy-
clic hydrocarbons [24]. These data are consistent with the idea
that polj is involved in relatively error-free bypass of polycy-
clic hydrocarbon lesions. However, the localisation of polj dif-
fers from that of the other Y-family polymerases. Although, it
is exclusively nuclear and is found in nuclear foci, the fraction
of cells with polj foci is much lower than that for polg, poli or
PCNA [34]. Furthermore, polj-deﬁcient cells are sensitive to
killing by UV light even though there is no evidence that polj
is able to bypass any type of UV lesion [23]. These ﬁndings
may suggest an additional role for polj.5. Polf and Rev1
The REV1, REV3 and REV7 genes were ﬁrst identiﬁed in S.
cerevisiae by their requirement for damage-induced mutagene-
sis [25]. The available evidence suggests that the same is likely
to be true for their mammalian orthologues [26,27]. A hetero-Fig. 2. Interactions involved in TLS. (A) Interactions of polg. The
green block represents polg with the conserved catalyric domain
shown as the thick bar. Lines above and below polg indicate the
regions involved in interactions with the indicated proteins. Data from
[13,14,19,30]. (B) Reported interactions between diﬀerent proteins
involved in TLS. Double-headed arrows indicate identiﬁed interac-
tions. Ubi, mono-ubiquitinated.dimer of Rev3 and Rev7 forms DNA polymerase f, a member
of the B-family of DNA polymerases [28], whereas Rev1 is
structurally a member of the Y-family, but is actually a dCMP
transferase, rather than a DNA polymerase [29]. Polf is able to
carry out extension reactions from nucleotides inserted oppo-
site various damaged sites, and it has been postulated that it
acts in conjunction with other polymerases, such as poli, which
can insert but not extend [18].
The function of hRev1 is something of an enigma. It is re-
quired for induced mutagenesis [27], and it colocalises with
polg, poli and PCNA in replication foci [30]. Furthermore,
the C-terminal 150 aa of hRev1 interacts with polg, poli, polj
and hRev7 [30–33]. These ﬁndings strongly suggest a role for
Rev1 in TLS, but the nature of this role remains obscure. It
has been suggested that it might act as a platform for switching
between TLS polymerases, but at present this remains specula-
tive [16].6. Conclusions
Many of the players involved in replication of DNA damage
have now been identiﬁed and we are just beginning to get some
insights into how they function at the sites of stalled replica-
tion forks and how they might be controlled. It is likely that
protein–protein interactions will provide the key to under-
standing some of these regulatory mechanisms (see Fig. 2).
In the case of polg, its interactions with PCNA and hRad18
are required for its localisation into replication foci and a spe-
ciﬁc interaction with mono-ubiquitinated PCNA mediates the
polymerase switch. Interactions of both polg and PCNA with
poli are needed to localise poli properly, and all the polyme-
rases interact with Rev1, although the biological function of
the latter is not yet understood.
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